Electromed (ELMD) Competitors $18.13 -0.08 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.11 -0.02 (-0.08%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELMD vs. AXGN, AVNS, KIDS, CBLL, BVS, SMLR, ZIMV, BFLY, DCTH, and TMCIShould you be buying Electromed stock or one of its competitors? The main competitors of Electromed include AxoGen (AXGN), AVANOS MEDICAL (AVNS), OrthoPediatrics (KIDS), CeriBell (CBLL), Bioventus (BVS), Semler Scientific (SMLR), ZimVie (ZIMV), Butterfly Network (BFLY), Delcath Systems (DCTH), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry. Electromed vs. Its Competitors AxoGen AVANOS MEDICAL OrthoPediatrics CeriBell Bioventus Semler Scientific ZimVie Butterfly Network Delcath Systems Treace Medical Concepts AxoGen (NASDAQ:AXGN) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Is AXGN or ELMD more profitable? Electromed has a net margin of 11.34% compared to AxoGen's net margin of -3.68%. Electromed's return on equity of 15.71% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets AxoGen-3.68% -7.09% -3.67% Electromed 11.34%15.71%13.37% Does the media favor AXGN or ELMD? In the previous week, AxoGen had 6 more articles in the media than Electromed. MarketBeat recorded 7 mentions for AxoGen and 1 mentions for Electromed. Electromed's average media sentiment score of 0.80 beat AxoGen's score of 0.47 indicating that Electromed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Electromed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AXGN or ELMD? AxoGen presently has a consensus target price of $24.50, indicating a potential upside of 93.37%. Electromed has a consensus target price of $33.50, indicating a potential upside of 84.78%. Given AxoGen's higher possible upside, equities research analysts clearly believe AxoGen is more favorable than Electromed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Electromed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00 Which has more risk and volatility, AXGN or ELMD? AxoGen has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Electromed has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Which has preferable earnings and valuation, AXGN or ELMD? Electromed has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxoGen$187.34M3.08-$9.96M-$0.15-84.47Electromed$61.44M2.47$5.15M$0.7922.95 Do institutionals & insiders believe in AXGN or ELMD? 80.3% of AxoGen shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 2.8% of AxoGen shares are held by company insiders. Comparatively, 14.0% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryElectromed beats AxoGen on 10 of the 17 factors compared between the two stocks. Get Electromed News Delivered to You Automatically Sign up to receive the latest news and ratings for ELMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELMD vs. The Competition Export to ExcelMetricElectromedElectromedical equipment IndustryMedical SectorNYSE ExchangeMarket Cap$152.04M$33.45M$5.48B$20.63BDividend YieldN/AN/A4.73%3.67%P/E Ratio24.173.0528.8929.01Price / Sales2.47198.51371.1465.92Price / Cash41.3641.3635.4522.82Price / Book3.551.788.264.43Net Income$5.15M-$2.66M$3.25B$993.74M7 Day Performance-3.67%-5.68%-3.73%-3.39%1 Month Performance-10.78%4.26%4.28%-2.10%1 Year Performance16.89%165.11%25.85%10.09% Electromed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELMDElectromed2.3917 of 5 stars$18.13-0.4%$33.50+84.8%+17.7%$152.04M$61.44M24.17160AXGNAxoGen2.3714 of 5 stars$12.99-2.8%$24.50+88.6%+55.3%$608.92M$187.34M0.00450Upcoming EarningsHigh Trading VolumeAVNSAVANOS MEDICAL2.3217 of 5 stars$12.02+0.1%N/A-53.7%$555.39M$687.80M8.642,227News CoverageUpcoming EarningsKIDSOrthoPediatrics3.885 of 5 stars$22.39-1.6%$35.83+60.0%-33.2%$552.52M$204.73M0.00200News CoverageUpcoming EarningsCBLLCeriBell2.5004 of 5 stars$14.96-1.1%$32.14+114.9%N/A$546.84M$65.44M0.00N/AUpcoming EarningsBVSBioventus1.01 of 5 stars$6.53-0.6%N/AN/A$539.69M$573.28M13.691,200SMLRSemler Scientific2.574 of 5 stars$39.25+3.1%$82.00+108.9%+14.4%$525.06M$56.29M11.30120Upcoming EarningsGap UpZIMVZimVie0.9358 of 5 stars$18.82+0.5%$17.00-9.7%-8.0%$521.30M$449.75M23.701,770News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeBFLYButterfly Network2.4271 of 5 stars$1.93-2.0%$3.50+81.3%+36.9%$487.16M$82.06M0.00460Trending NewsAnalyst DowngradeGap DownDCTHDelcath Systems2.6982 of 5 stars$11.41flat$24.00+110.3%+29.3%$397.37M$37.21M0.0060Upcoming EarningsAnalyst UpgradeTMCITreace Medical Concepts2.4138 of 5 stars$5.75+0.9%$10.52+82.9%-19.0%$358.47M$209.36M0.00250News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies AXGN Competitors AVNS Competitors KIDS Competitors CBLL Competitors BVS Competitors SMLR Competitors ZIMV Competitors BFLY Competitors DCTH Competitors TMCI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ELMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Electromed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Electromed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
